Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.72 |
| ▸ | RHOA | P61586 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011712 | 0.84 | TRPV1 (1.00) | TRPV1RHOABACE1MAPTMEN1 | |
| SCHEMBL1013650 | 0.84 | TRPV1 (1.00) | TRPV1RHOABACE1MAPTABL1 | |
| SCHEMBL656782 | 0.81 | ABCB1 (0.61) | TRPV1RHOAMAPTMEN1ALDH1A1 | |
| SCHEMBL2305280 | 0.78 | TP53 (0.74) | BACE1MAPTTP53MEN1ALDH1A1 | |
| SCHEMBL4021308 | 0.78 | TRPV1 (0.57) | TRPV1RHOABACE1MAPTTP53 | |
| SCHEMBL4836061 | 0.77 | TRPV1 (0.87) | TRPV1BACE1MAPTABL1 | |
| SCHEMBL12907690 | 0.75 | TP53 (0.64) | BACE1MAPTTP53MEN1ALDH1A1 | |
| SCHEMBL4666194 | 0.75 | TP53 (0.61) | BACE1MAPTTP53MEN1ALDH1A1 | |
| SCHEMBL657416 | 0.73 | KDM1A (0.62) | RHOAMAPTTP53MEN1ALDH1A1 | |
| SCHEMBL4833186 | 0.72 | TRPV1 (0.80) | TRPV1BACE1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | claimed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | claimed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885RHOA 836/4885BACE1 1021/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885RHOA 939/4885BACE1 1269/4885 |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885RHOA 939/4885BACE1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.